

**National Institute for Health and Care Excellence (NICE) Guidance (Table 1) APRIL 2018**

No.	Title <a href="#">(click link)</a>	Findings/ Recommendations/Conclusions	Implications/For Discussion	Commissioners	
TA517	<a href="#">Avelumab for treating metastatic Merkel cell carcinoma</a>	Recommended as an option in those who have received at least 1 line of chemotherapy for metastatic disease. Also recommended as an option for use in the Cancer Drugs Fund in those who haven't received previous chemotherapy.	Minimal cost estimated at £9,100 per 100,000 population because of the rarity of the disease.	NHS England	
TA518	<a href="#">Tocilizumab for treating giant cell arteritis</a>	Recommended as an option in patients (who haven't received tocilizumab previously) with relapsing/refractory disease. Must be stopped after a maximum of 1 year of uninterrupted treatment	Around 400 people estimated to receive tocilizumab in England per annum. Costing template for local use is available.	NHS England	
TA519	<a href="#">Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy</a>	Recommended for use within the Cancer Drugs Fund. Must be stopped at 2 years or earlier if disease progresses.	Managed by CDF.	NHS England	
NG95	<a href="#">Lyme disease</a>	Covers diagnosis and management. Caused by a bacterium present on ticks, usually found in grassy and wooded areas. Can present as fever, malaise, joint pain and cognitive impairment. Detailed recommendations on diagnosis, referral and treatment.	Main treatments are doxycycline, amoxicillin and ceftriaxone. May be a requirement for GP education.	CCG, NHS England and LAs.	
NG96	<a href="#">Care and support of people growing older with learning disabilities</a>	Recommendations on equitable access to services, provision of information in an appropriate format, mental capacity and consent and involvement of carers. Additional recommendations on service planning, general and needs assessment, housing and coordination of care.	Mainly intended for social care, commissioners, NHS and related services. Additional costs may occur as a result of introduction of community support services and transport systems. Commissioners may wish to review current provision in light of the new guidance.	CCG and LAs.	
CG192	<a href="#">Antenatal and postnatal mental health: clinical management and service guidance</a>	<b>UPDATE:</b> First published in 2014. Takes into account MHRA's latest advice on prescription of sodium valproate	May be a requirement for GP education.		
CG185	<a href="#">Bipolar disorder: assessment and management</a>	<b>UPDATE:</b> First published in 2014. Takes into account MHRA's latest advice on prescription of sodium valproate	As above.		
CG173	<a href="#">Neuropathic pain in adults: pharmacological management in non-specialist settings</a>	<b>UPDATE:</b> First published in 2013. Takes into account MHRA's latest advice on prescription of sodium valproate	As above.		

CG137	<a href="#">Epilepsies: diagnosis and management</a>	<b>UPDATE:</b> First published in 2012. Takes into account MHRA's latest advice on prescription of sodium valproate	As above.		
CG90	<a href="#">Depression in adults: recognition and management</a>	<b>UPDATE:</b> First published in 2009. Takes into account MHRA's latest advice on prescription of sodium valproate	As above.		
DG32	<a href="#">Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I</a>	The Dynamic Spectral Imaging System (DYSIS) shows promise. The Zedscan I also shows promise but evidence is limited.	The DYSIS it is recommended for use but outcomes should be audited. The Zedscan I cannot be recommended for routine use		
IPG609	<a href="#">Robot-assisted kidney transplant</a>	Current evidence on safety and efficacy is limited in quantity and quality.	Should only be used in the context of research in most patients. For patients with obesity, should only be used with special arrangements for clinical governance, consent and audit or research.		
IPG610	<a href="#">Nerve transfer to partially restore upper limb function in tetraplegia</a>	Evidence is limited in quantity. No major safety concerns.	Should only be used with special arrangements for clinical governance, consent and audit or research.		
IPG611	<a href="#">Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia</a>	Aim is to reduce blood supply to prostate with resultant necrosis. Current evidence on safety and efficacy is adequate.	Normal arrangements for clinical governance, consent and audit.		
IPG612	<a href="#">Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma</a>	Evidence is inadequate.	Special arrangements for clinical governance, consent and audit or research.		
MIB142	<a href="#">ColonFlag for identifying people at risk of colorectal cancer</a>	Web based machine learning algorithm designed to identify people over 40 years at high risk. Uses existing datasets such as age, sex and blood counts. Data from 4 observational studies.	No published evidence detailing the resource consequences or patient outcomes.		
MIB143	<a href="#">Curos disinfecting cap for needleless connectors</a>	Avoids the need for manual disinfection.	Evidence is of limited quality. An RCT is required.		
MIB144	<a href="#">Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema</a>	Device emits specific wavelength of light during sleep and it reduces the production of vascular endothelial growth factors.	Evidence is very limited in quantity and quality. No data on cost effectiveness.		

**IPG** = Interventional Procedure Guidance **CG** = Clinical Guideline **TA** = Technology Appraisal **PHG** = Public Health Guidance **PSG** = Patient Safety Guidance

**MIB:** Medtech Innovation Briefing **MTG** = Medical Technology Guidance **DG** = Diagnostics Guidance **SSG** = Safe Staffing Guideline **HST** = Highly Specialised Technology Guidance

**NG** = NICE guideline

**Table 2: QUALITY STANDARDS :** No quality standards published this month

**Table 3: Evidence summaries (ES) and Key therapeutic topics (KTT):** No summaries published this month.